KLK3 and prostate cancer: Smith Smith M M Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time J Clin Oncol J Clin Oncol 2013 2013 31 31 3800 3800 3806 3806 10.1200/JCO.2012.44.6716 10.1200/JCO.2012.44.6716 24043751 24043751